文献速递细菌感染、耐药与抗菌药物

临床噬菌体微生物学:叙述性综述

Clinical phage microbiology: a narrative summary.
PubMed 文献 · Clin Microbiol Infect · 2023-02-16

噬菌体治疗因抗菌药物耐药和留置医疗器械相关生物膜感染而重新受到关注,但临床疗效不一致,原因包括噬菌体宿主范围窄、感染部位浓集困难、细菌对噬菌体产生耐药及免疫中和。本文通过PubMed检索综述临床噬菌体微生物学现状,指出噬菌体敏感性试验、生物膜试验、噬菌体-抗生素联合试验、治疗药物监测和免疫监测是当前临床噬菌体诊断的基础,但标准化及临床应用管理仍需明确,体外研究与体内结局之间存在显著差距。

要点

  • 噬菌体敏感性试验、生物膜试验、联合试验、治疗药物监测和免疫监测是临床噬菌体诊断的当前基础。
  • 这些检测需标准化,并需更好理解其是否及如何用于接受噬菌体治疗患者的临床管理。
  • 体外研究与体内结局之间存在显著差距,需进一步研究噬菌体药代动力学以准确检测感染部位噬菌体颗粒。

核心结论

  • 临床噬菌体微生物学检测是当前临床噬菌体诊断的基础,但标准化及临床管理中的应用仍需明确。
  • 体外研究与体内结局之间存在显著差距,需进一步研究噬菌体药代动力学以准确检测感染部位噬菌体颗粒。
  • 需重现体内生物膜并捕捉噬菌体与抗生素、靶细菌、鸡尾酒中噬菌体之间及与超宿主免疫系统的复杂相互作用。

研究设计与样本

  • 叙述性综述,通过PubMed检索,检索词包括「噬菌体微生物学」「噬菌体敏感性试验」「噬菌体宿主范围」「噬菌体生物膜」和「噬菌体治疗监测」。

主要发现

  • 临床噬菌体治疗成功不一致的原因包括噬菌体宿主范围窄、感染部位浓集噬菌体困难、细菌对噬菌体产生耐药及免疫中和。
  • 噬菌体敏感性试验、生物膜试验、噬菌体-抗生素联合试验、治疗药物监测和免疫监测是当前临床噬菌体诊断的基础。
  • 体外研究与体内结局之间存在显著差距,需进一步研究噬菌体药代动力学以准确检测感染部位噬菌体颗粒。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although phage therapy has been in existence for a century, a recent resurgence in interest has occurred because of the continued emergence of antimicrobial resistance and the rising use of indwelling medical devices, resulting in biofilm-associated infections, for which conventional antibiotics are of limited use. Despite this, the clinical successes have been inconsistent because of multiple reasons, including (1) the narrow host range of phages, (2) challenges with concentrating phages at the site of infection, (3) development of resistance of bacteria to phages and (4) immune neutralization. Microbiologic assays have the potential to help guide the course of clinical therapy and improve outcomes. Methods developed decades ago remain the mainstay of phage diagnostics and recently, newer diagnostics are closing the gap needed to further advance clinical phage therapy. OBJECTIVES: To review the current state of clinical phage microbiology and identify gaps. SOURCES: A PubMed search was performed using the terms "phage microbiology", "phage susceptibility test", "phage host range", "phage biofilm", and "phage therapeutic monitoring". CONTENT: Phage susceptibility testing, biofilm assays, phage-antibiotic combination testing, therapeutic drug monitoring, and immune monitoring assays are the current foundation for clinical phage diagnostics. Standardization of these assays and better understanding as to if and how they should be used in terms of clinical management of patients receiving phage therapy is needed. IMPLICATIONS: A substantial gap between in vitro studies and in vivo outcomes indicates that further work is needed in phage pharmacokinetics to accurately assay phage particles at the site of infection; recapitulate in vivo biofilm; capture the complex interactions between phages and antibiotics, phages and their target bacteria, among phages in a cocktail, and with the superhost immune system.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Suh GA, Patel R. Clinical phage microbiology: a narrative summary. Clin Microbiol Infect. 2023. PMID: 36805835. doi:10.1016/j.cmi.2023.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。